Olaparib Approved for Metastatic Pancreatic Cancer.
Olaparib Approved for Metastatic Pancreatic Cancer. Am J Nurs. 2020 Apr;120(4):22-23 Authors: Aschenbrenner DS PMID: 32218041 [PubMed - as supplied by publisher]
CONCLUSIONS: LINC00473 was upregulated in PC tissues and cells, indicating a poor prognosis and clinical pathological features of PC. It promoted PC progression via activating the cAMP/β-catenin axis, which provided a novel target for the prediction for PC diagnosis, biological therapy, and prognosis. PMID: 32495868 [PubMed - in process]
Authors: Zhao HW, Zhou N, Jin F, Wang R, Zhao JQ Abstract OBJECTIVE: To study the influences of metformin on the proliferation and apoptosis of pancreatic cancer cells and its dose-effect relationship and crucial molecular mechanism. MATERIALS AND METHODS: With human pancreatic cancer cell line PANC-1 as the study object, different concentrations of metformin were added for intervention. Then, the proliferation of PANC-1 cells was detected via methyl thiazolyl tetrazolium (MTT) assay to determine the dose-effect relationship of metformin in PANC-1 cell proliferation. PANC-1 cells were treated with metformin at ...
Conclusion: Elevated pretreatment CAR may independently predict poor OS in pancreatic cancer patients. Pretreatment CAR is possibly a simple and cost-effective blood-derived indicator for predicting survival outcome in patients with pancreatic cancer.
Several minimally invasive image guided tumor ablation techniques have been added to the treatment spectrum for locally advanced pancreatic cancer (LAPC). Irreversible electroporation (IRE) might have a significant additive value in the management of this difficult-to-treat disease.As opposed to thermal ablative techniques, IRE induces cell death by the delivery of high-voltage electrical pulses. The electrical energy disrupts the cellular membrane integrity, causes loss of cellular homeostasis and ultimately results in cell death.
ConclusionsHerein, the expression profiles, oncogenic roles, regulators and inhibitors of DNMT1 in PDACs are presented and discussed. DNMT1 is overexpressed in PDAC cases compared with non-cancerous pancreatic ducts, and its expression gradually increases from pre-neoplastic lesions to PDACs. DNMT1 plays oncogenic roles in suppressing PDAC cell differentiation and in promoting their proliferation, migration and invasion, as well as in induction of the self-renewal capacity of PDAC cancer stem cells. These effects are achieved via promoter hypermethylation of tumor suppressor genes, including cyclin-dependent kinase inhibit...
Conclusion: CBP/β-catenin antagonism represents a novel therapeutic strategy for suppressing PSC activation and may be effective at countering PSC promotion of pancreatic cancer.
Authors: Surinach A, Phung T, Abdul-Rahim O, Khushman M Abstract At 9%, and 2% when diagnosed at advanced stage, the 5-year relative survival rate for pancreatic ductal adenocarcinoma (pdac) is the lowest of any cancer. The currently approved treatment options for metastatic pdac in the United States are folfirinox [irinotecan-fluorouracil (5fu)-leucovorin (lv)-oxaliplatin], gemcitabine-nab-paclitaxel, and liposomal irinotecan plus 5fu-lv. Liposomal irinotecan is a novel formulation of irinotecan encapsulated within a lipid bilayer, which favours local metabolic activation. The napoli-1 trial demonstrated the effic...
Condition: Pancreatic Cancer Interventions: Drug: Camrelizumab; Drug: Apatinib Sponsor: Zhejiang Cancer Hospital Recruiting
Contributors : Stephen Neidle ; Ahmed AhmedSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTargeting quadruplexes in cancer genes and pathways by a novel class of asymmetrically-substituted napththalene diimides (SOP1812) with potent cellular and antitumour activity in models for pancreatic cancer.
Which of these is better for my adversity essay for secondaries: 1) My mom was diagnosed with stage 3 pancreatic cancer at the end of my second year in undergrad. I had to drive back and forth from school (2 hour trip) to take care of her and attend her chemo sessions and surgeries in addition to keeping of my school work and activities. 2) I moved around a lot cross-county when I was growing up. I only went to each school for K-12 for a max of 2 years before changing schools. This led to... Adversity topic for secondaries